Alexion Pharmaceuticals Receives Marketing Authorization From EC For Ultomiris For Adults With PNH
July 3 (Reuters) - Alexion Pharmaceuticals Inc
Latest Developments forAlexion Pharmaceuticals Inc
- Alexion Pharmaceuticals Q2 Non-GAAP Earnings Per Share $2.64
- Alexion Pharma Reports Positive Extension Data From Late-Stage Study of Ultomiris In Patients With Paroxysmal Nocturnal Hemoglobinuria
- Alexion Pharmaceuticals Posts Q1 Earnings Per Share Of $2.61
- Alexion Announces Interim Data From Phase 3 Study Of Soliris In Adults With Generalized Myasthenia Gravis In Muscle & Nerve